Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 9 (3), 153-66

Cell Cycle, CDKs and Cancer: A Changing Paradigm

Affiliations
Review

Cell Cycle, CDKs and Cancer: A Changing Paradigm

Marcos Malumbres et al. Nat Rev Cancer.

Abstract

Tumour-associated cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity. Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability. According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumour cells. However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells. Emerging evidence suggests that tumour cells may also require specific interphase CDKs for proliferation. Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.

Trial registration: ClinicalTrials.gov NCT00141297 NCT00147485 NCT00292864 NCT00372073 NCT00390117 NCT00400296 NCT00407498 NCT00446342 NCT00772876.

Similar articles

See all similar articles

Cited by 977 articles

See all "Cited by" articles

References

    1. Nat Cell Biol. 2008 Jul;10 (7):802-11 - PubMed
    1. Cell. 1994 Jul 15;78(1):67-74 - PubMed
    1. Nat Genet. 2006 Sep;38(9):1043-8 - PubMed
    1. Oncogene. 2008 Feb 7;27(7):907-17 - PubMed
    1. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7491-5 - PubMed

Publication types

Associated data

LinkOut - more resources

Feedback